Blood Transfusion Management and Transfusion-related Outcomes in Daratumumab-treated Patients With Relapsed or Refractory Multiple Myeloma

Conclusion In SIRIUS, no RBC transfusion reactions, including hemolysis, were observed. Observations from Mount Sinai and Levine Cancer Institute, confirm that transfusions may be administered safely to daratumumab-treated patients. Graphical abstract Teaser Daratumumab binds CD38 on red blood cells (RBCs), resulting in panagglutination in blood compatibility tests. RBC transfusions and transfusion-related adverse events from the phase 2 SIRIUS clinical trial were analyzed and an in-depth analysis from 2 clinical study sites is reported. RBC transfusion-related adverse events, including hemolysis, were not observed among daratumumab-treated patients, confirming that transfusions may be safely administered.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research